Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment.
Title | Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment. |
Publication Type | Journal Article |
Year of Publication | 2010 |
Authors | Gerasimou, G., Moralidis E., & Gotzamani-Psarrakou A. |
Journal | Hell J Nucl Med |
Volume | 13 |
Issue | 2 |
Pagination | 158-62 |
Date Published | 2010 May-Aug |
ISSN | 1790-5427 |
Keywords | Gastrointestinal Neoplasms, Humans, Lung Neoplasms, Molecular Imaging, Neuroendocrine Tumors, Receptors, Somatostatin, Somatostatin |
Abstract | Somatostatin is a neuropeptide that confers a wide range of pharmacological properties. Indium-111-tagged pentetreotide ((111)In-P) is a radiolabeled analogue of somatostatin indicated for the in vivo scintigraphic localization of neuroendocrine tumors (NET). In cases of NET of the gastro-intestinal tract we describe the sensitivity compared to conventional anatomical imaging modalities and especially the possibility that (111)In-P may change therapeutic management into up one fourth of the patients. In cases of small cell lung carcinoma it has been used for the evaluation of somatostatin receptor status and a substantial tool for differentiation between limited and extensive disease, especially when combined with anatomical imaging methods. We also describe the radiolabeled with yttrium-90 or lutetium-177 somatostatin analogue peptides in the treatment of NET and also the use of (111)In-P for the selection of patients for targeted treatment. |
Alternate Journal | Hell J Nucl Med |
PubMed ID | 20808990 |